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ABSTRACT Absence of a common diagnostic interview has hampered cross-national syntheses of epidemiological
evidence on major depressive episodes (MDE). Community epidemiological surveys using the World Health Organization
Composite International Diagnostic Interview administered face-to-face were carried out in 10 countries in North America
(Canada and the US), Latin America (Brazil, Chile, and Mexico), Europe (Czech Republic, Germany, the Netherlands,
and Turkey), and Asia (Japan). The total sample size was more than 37,000.
Lifetime prevalence estimates of hierarchy-free DSM-III-R/DSM-IV MDE varied widely, from 3% in Japan to 16.9%
in the US, with the majority in the range of 8% to 12%. The 12-month/lifetime prevalence ratio was in the range 40% to
55%, the 30-day/12-month prevalence ratio in the range 45% to 65%, and median age of onset in the range 20 to 25 in
most countries. Consistent socio-demographic correlates included being female and unmarried. Respondents in recent
cohorts reported higher lifetime prevalence, but lower persistence than those in earlier cohorts. Major depressive episodes
were found to be strongly co-morbid with, and temporally secondary to, anxiety disorders in all countries, with primary
panic and generalized anxiety disorders the most powerful predictors of the first onset of secondary MDE.
Major depressive episodes are a commonly occurring disorder that usually has a chronic-intermittent course.
Effectiveness trials are needed to evaluate the impact of early detection and treatment on the course of MDE as well as to
evaluate whether timely treatment of primary anxiety disorders would reduce the subsequent onset, persistence, and
severity of secondary MDE.
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Introduction
Community epidemiological surveys of mental
disorders, using some combination of structured
screening scales and clinical interviews, have been
carried out since the end of the Second World War
(see, for example, Lin, 1953 and Helgason, 1964).
However, in the absence of a common format for
diagnostic interviews, few cross-national syntheses
were made until the past decade. The foundation for
recent syntheses was laid in the early 1980s with the
development of the Diagnostic Interview Schedule
(DIS) (Robins et al., 1981), the first fully structured
research diagnostic interview that could be used by lay
interviewers to generate diagnoses according to the
definitions and criteria of the Diagnostic and Statistical
Manual of Mental Disorders, third edition (DSM-III)
(American Psychiatric Association, 1980). The DIS
was first used in the Epidemiologic Catchment Area
(ECA) Study (Robins and Regier, 1991), a landmark
survey of the prevalences and correlates of mental
disorders in the US. The widespread dissemination of
the ECA results led to a number of similar studies in
other countries (Canino et al., 1987; Bland et al.,
1988a; Hwu et al., 1989; Lépine et al., 1989; Wells et
al., 1989; Lee et al., 1990; Wittchen et al., 1992).
These surveys were subsequently brought together in a
series of important cross-national comparative papers
that focused on specific disorders (Cross-National
Collaborative Group, 1992; Weissman et al., 1996,
1997). 
Beginning in the mid-1980s, the World Health
Organization (WHO), in collaboration with the US
Public Health Service, attempted to build on the
success of the DIS and to encourage further cross-
national collaboration by developing a fully structured
research diagnostic interview based on the DIS that
could generate reliable and valid diagnoses in many
different languages throughout the world. This new
instrument, known as the Composite International
Diagnostic Interview (CIDI), was created by an inter-
national WHO working group that expanded and
refined the DIS to include ICD (International
Classification of Diseases) criteria (Robins et al.,
1988). Cross-national field trials showed the CIDI to
be reliable and valid cross-nationally (Wittchen,
1994). Version 1.0 of the CIDI was released in 1990
(World Health Organization, 1990) and was subse-
quently revised to include DSM-IV criteria (World
Health Organization, 1997). 
In the decade since it first became available, the CIDI
has been used in a number of large-scale community
epidemiological surveys throughout the world (Kessler
et al., 1994; Andrade et al., 1996; Bijl et al., 1998;
Caraveo et al., 1998; Kılıç, 1998; Vega et al., 1998;
Offord et al., 1994; Dragomirecká et al., 2002; Wittchen
et al., 1998).
In recognition of this widespread use, the
WHO created a research consortium – the WHO
International Consortium in Psychiatric Epidemiology
(ICPE) – to co-ordinate comparative analyses of these
data (Kessler, 1999). This article presents findings
from the first generation of ICPE surveys on the
epidemiology of major depressive episodes (MDE).
Data are presented from surveys carried out between
1990 and 1999 in 10 countries with a combined
sample size of approximately 37,000 respondents. 
Methods
Samples
A total of 10 surveys were carried out in North
America (Canada and the USA), Latin America
(Brazil, Chile and Mexico), Europe (Czech Republic,
Germany, Netherlands, and Turkey), and Asia
(Japan). All the surveys were based on probability
samples of the general population, and all interviews
were carried out face-to-face by trained lay inter-
viewers. As shown in Table 1, the pooled sample
included respondents as young as 14 years of age.
Across surveys, the response rates were in the range
56.9% to 90.3%. The data sets in Canada, Chile,
Germany, the Netherlands, and the US were weighted
to adjust for differences between the socio-
demographic characteristics of the samples and the
populations from which they were selected. These
adjustments were not possible in the other data sets
because of a lack of population data.
Measures
The surveys used either the WHO-CIDI (in Brazil,
Chile, Czech Republic, Netherlands, Turkey), the
University of Michigan version of CIDI (UM-CIDI)
(Kessler et al., 1998a) (Canada, Japan, Mexico and the
USA), or the Munich version of CIDI (M–CIDI)
(Wittchen et al., 1996) (Germany). The UM-CIDI
added a series of commitment and clarification probes
to the original CIDI in order to increase the accuracy
of responses about lifetime prevalence. It also included
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a review of lifetime diagnostic stem questions at the
beginning of the interview in order to facilitate active
memory search. Experimental evidence shows that
these modifications led to a substantial increase in
lifetime prevalence estimates (Kessler et al., 1998a).
Compared with the original CIDI, the expanded
questions in the M-CIDI helped to investigate disorder
subtypes and to increase accuracy of assessing
diagnostic criteria. Diagnostic assessments were based
on DSM-III-R (American Psychiatric Association,
1987) criteria in all countries other than Germany,
where DSM-IV (American Psychiatric Association,
1994) criteria were used. 
Retrospective reports were used to estimate age of
onset. The core disorders included in the surveys were
anxiety disorders (panic disorder, agoraphobia with
and without panic, social anxiety disorder, simple
phobia, generalized anxiety disorder, obsessive-
compulsive disorder, post-traumatic stress disorder),
mood disorders (major depressive disorder, dysthymia,
mania), and substance-use disorders (alcohol and drug
abuse/dependence). The CIDI organic exclusion rules
were imposed in making all diagnoses. Diagnostic
hierarchy rules were used for substance-use disorders
but not for mental disorders. Methodological evidence
gathered in the WHO-CIDI field trials showed that all
the lifetime DSM/CIDI disorders considered here were
assessed with acceptable reliability and validity in the
WHO-CIDI (Wittchen, 1994). Clinical reappraisal
studies carried out in conjunction with two of the
ICPE surveys, the US National Comorbidity Survey
(Kessler et al., 1998a) and the German Early
Developmental Stages of Psychopathology study
(Wittchen et al., 1996; Reed et al., 1998), documented
acceptable reliability and validity for lifetime
diagnoses based on the UM–CIDI and M–CIDI. No
validity data are available for the 12-month or 30-day
prevalence estimates.
Analysis methods
Data are reported here on prevalences, co-morbidities,
cohort effects, age-of-onset distributions, demographic
correlates, effects of temporally primary disorders in
predicting the subsequent first onset of an MDE, speed
of initial treatment contact, and patterns of 12-month
service use. Simple cross-tabulations were used to
calculate prevalences. Odds-ratios (ORs) were used
to calculate co-morbidities. The Kaplan–Meier
method (Kaplan and Meier, 1958) was used to
generate age-of-onset curves. Logistic regression
analysis (Hosmer and Lemeshow, 1989) was used to
study demographic correlates. Discrete-time survival
analysis (Efron, 1988) with the person-year as the unit
of analysis was used to study cohort effects, the effects
of temporally primary disorders on secondary MDE,
and predictors of speed of initial treatment contact.
Owing to the complex sample designs and
weighting of the surveys, standard errors of the various
descriptive statistics were estimated using the jacknife
repeated replications (JRR) method (Kish and
Frankel, 1974) implemented in an SAS macro. The
JRR estimates adjust for the clustering and weighting
of cases. The logistic regression and survival coeffi-
cients were transformed to ORs and are reported below
as ORs with 95% confidence intervals (CIs). The 95%
CIs were adjusted for design effects. Multivariate tests
were based on Wald χ2 tests computed from co-
efficient variance–covariance matrices that were
adjusted for design effects using JRR. Statistical signifi-
cance was based on two-sided design-based tests
evaluated at the 0.05 level of significance.
Results
Demographic characteristics of the samples
The demographic distributions of the samples are
presented in Table 2. As noted above, the results were
weighted to approximate the population census distri-
bution in five of the samples (Canada, Chile,
Germany, Netherlands and the US), but were
weighted only for differential probability of selection
in households in the other samples. It is therefore not
legitimate to compare the patterns across all the
samples. Nonetheless, some general observations are
worth making. Age distributions varied considerably
owing to differences in the age restrictions of sample
participation. Distribution between the sexes was fairly
evenly divided. Distribution in education varied
dramatically because of cross-national differences in
schooling. The majority of respondents in most surveys
were married at the time of interview, although this
was not the case in Germany because of the young age
range of this sample. Rural–urban distribution was
predominantly urban in all the surveys but was 100%
urban, by definition, in the surveys carried out in
Brazil, Chile, Japan, and Mexico. Although the
German sample was also largely urban, non-urban
areas were included in the sampling frame.
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Prevalence 
The lifetime prevalence of MDE based on DSM-III,
DSM-III-R, DSM-IV, and ICD-10 criteria has been
estimated in a number of community epidemiological
surveys, most of them carried out in industrialized
countries (Weissman and Myers, 1978; American
Psychiatric Association 1980, 1987, 1994; Bebbington
et al., 1981; Canino et al., 1987; Lee et al., 1987;
Bebbington, 1988; Bland et al., 1988a,b; Cheng, 1989;
Hwu et al., 1989; Wells et al., 1989; Wittchen et al.,
1992).
There is enormous variation in these estimates,
between 4% and 20% lifetime prevalence. This
variation is presumably due to differences in popula-
tions studied, criteria used to generate diagnoses,
survey response rates, and methodological features of
the surveys that influence accuracy of response.
However, little is known about the relative importance
of these different factors. Twelve-month MDE preva-
lence estimates in these epidemiological surveys are
generally between one-third and half as high as
lifetime prevalence estimates, whereas 30-day preva-
lence estimates are usually between one-third and half
as high as 12-month prevalence estimates. 
As shown in Table 3, the range of lifetime preva-
lence estimates in the ICPE surveys is similar to
previous literature reports, from a low of 3% in Japan
to a high of 16.9% in the US. Only in the Japanese
survey was lifetime prevalence less than 5%, compared
with five surveys with lifetime prevalence in the range
5% to 10%, two in the range 10% to 15%, and two
greater than 15%. Twelve-month prevalence estimates
range from 1.2% (Japan) to 10% (US), with seven of
the 10 estimates clustered in the range 3.5% to 5.9%.
Thirty-day prevalence estimates range from 0.9%
(Japan) to 4.6% (US), with six of the 10 estimates
clustered in the range 1.9% to 3.9%.
Course
The finding in previous community epidemiological
surveys that the 12-month prevalence of MDE is
between one-third and half as large as the lifetime
prevalence suggests that MDE is a very chronic
disorder. The finding in these same surveys that the
30-day prevalence is between one-third and one-half
as large as 12-month prevalence suggests that MDE is
an intermittent disorder. That is, people with the
disorder typically have recurrent episodes that persist
for less than a full year. Longitudinal studies in clinical
samples find similar patterns (Solomon et al., 2000).
Table 4 presents ratios of the lifetime, 12-month,
and 30-day prevalence estimates of MDE in the ICPE
surveys. The ratio of 12-month to lifetime prevalence
ranges from 24.4% (Czech Republic) to 62.6%
(Chile), with six of the 10 estimates clustered in the
range 42% to 55.5%. The ratio of 30-day to 12-month
prevalence ranges from 24.4% (Germany) to 88.1%
(Turkey), with seven of the 10 estimates clustered in
the range 44.9% to 67.2%. The ratio of 30-day to
lifetime prevalence ranges from 11.0% (Germany)
to 63.6% (Turkey), with six of the 10 estimates
clustered in the range 23.3% to 37.4%. These results
are generally consistent with those of previous studies
in suggesting that MDE is a chronic disorder (high 12-
month/lifetime prevalence ratio) that is usually
intermittent in its course (30-day/12-month preva-
lence ratio considerably lower than 1). 
Disaggregation of the lifetime/12-month and 30-
day/12-month prevalence ratios as a function of
number of years since first onset of MDE (results not
shown, but available on the ICPE Web page
www.hcp.med.harvard.edu/icpe) show that the ratios
typically decline, but nonetheless remain substantial,
across the distribution of time since onset. For
example, in seven of the 10 countries, among respon-
dents whose first onset of MDE was more than a
decade ago, at least one-third of people with lifetime
MDE had an episode in the 12 months before the
interview. This shows that recurrence risk continues
for years after first onset. It is also noteworthy that the
30-day/12-month prevalence ratio remains fairly stable
over time in most countries, suggesting that the
average duration of episodes does not change over
time.
Further evidence along the same lines comes from
reports of respondents who met criteria for lifetime
MDE about the course of their illness. Recurrent
episodes were reported by nearly 75% of respondents
with lifetime MDE. The mean and median numbers
of lifetime episodes among recurrent cases were four
and 16, respectively. The mean duration of the
longest lifetime episode was approximately three
months, whereas fewer than one in eight respondents
with lifetime MDE reported ever having an episode
that lasted as long as two years, this being the
minimum duration for a chronic depressive episode
in the DSM-IV system (American Psychiatric
Association, 1994).
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Age of onset
Previous epidemiological studies have found that MDE
has a much earlier age of onset than most other
chronic conditions, with risk beginning to appear in
early adolescence. The median age of onset is in the
early-to-mid twenties, but risk of MDE continues
throughout the life course (Christie et al., 1988; Blazer
et al., 1994). Data about the age of onset from the
ICPE survey were acquired by using retrospective age-
of-onset reports obtained from respondents who met
lifetime criteria for MDE. Age-of-onset curves were
generated from these reports using the Kaplan–Meier
method (Kaplan and Meier, 1958). Country-specific
results are shown graphically in Figure 1. Results have
been standardized for between-country differences in
lifetime prevalence. The median age of onset of MDE
is predominantly in the early to mid-twenties in all
countries other than Japan (late twenties) and the
Czech Republic (early thirties). The curves have a
consistent shape across all the countries, with risk
being fairly low in the early years of life, rising during
adolescence and through the middle-to-late twenties,
and then decreasing in later years. 
Sociodemographic correlates
Previous epidemiological studies have found that MDE
is more common among women than men, among
people with lower than higher socioeconomic status
(low income and education), and among the
unmarried than the married (Canino et al., 1987;
Bland et al., 1988a; Hwu et al., 1989; Lépine et al.,
1989; Wells et al., 1989; Lee et al., 1990; Wittchen et
al., 1992). The results in Table 5 show the associations
of 12-month MDE with these sociodemographic corre-
lates in the ICPE surveys. (Results were found to be
very similar across the lifetime, 12-month, and 30-day
time frames, so only the predictors of 12-month preva-
lence are presented here.) The most consistent
association in the table is with gender. Women have
higher rates of MDE than men in all 10 countries, with
ORs ranging from 1.2 in the Czech Republic to 2.5 in
Japan. ORs for female:male in eight of the 10 countries
are statistically significant at the 0.05 level and 9 of
the 10 are tightly clustered in the range 1.9–2.5. 
The associations of socioeconomic status with 12-
month MDE are considerably weaker than those
involving gender. Education is significantly related to
Figure 1. Age-of-onset distributions of major depressive episodes in the ICPE surveys.
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MDE in only two of the 10 countries (the US and the
Netherlands), whereas family income (divided into
within-country quartiles) is significantly related to
MDE in three of the five countries in which income
was assessed (US, Canada, and the Netherlands).
Unmarried people have higher rates of MDE than
those that are married in all 10 surveys, with ORs
ranging from 1.1 in Brazil and Turkey to 2.5 in
Germany. The ORs for four of the 10 countries are
statistically significant at the 0.05 level and seven of
the 10 are meaningfully elevated in the range 1.5
to 2.5. Urban-rural difference was also studied.
Rural respondents were slightly less likely than urban
respondents to have MDE in five of the six countries
where urbanicity could be studied, with ORs ranging
from 0.6 in The Netherlands to 1 in Germany. Only
one of the six (the Netherlands) was statistically
significant at the 0.05 level. 
The final sociodemographic correlate studied was
age. A number of epidemiological surveys have shown
that age is inversely related to MDE (Weissman and
Myers, 1978; Canino et al., 1987; Bland et al., 1988b)
although an earlier analysis of the ICPE surveys that
focused on overall mood disorders found that this
relationship is more true for lifetime prevalence than
for recent prevalence (WHO International
Consortium of Psychiatric Epidemiology, 2000). As
shown in the last rows of Table 5, the association of
age with 12-month MDE is not apparent in the ICPE
surveys. This association is statistically significant in
only one of the 10 countries (the Netherlands). Even
in this one case, the highest risk was not found in the
youngest cohort. There were only two countries (Japan
and the US) where the risk was highest in the
youngest cohort. 
Cohort effects
As noted in the last paragraph, previous analyses of the
ICPE data found a much stronger inverse relationship
between age and lifetime than recent mood disorders
(MDD, bipolar disorder, or dysthymia). The association
between age and lifetime risk, which was evaluated in a
survival framework that adjusted for age differences in
time at risk, can be interpreted substantively as a
‘cohort effect’, by which we mean an increase in the
lifetime prevalence of mental disorders across
successive generations. This possibility was evaluated
using retrospective age-of-onset reports to estimate a
series of survival models for lifetime prevalence as
a function of age at interview. The results are presented
in Table 6, which shows consistent and statistically
significant evidence for increasing lifetime prevalence
of MDE in more recent cohorts across all nine of the
countries in which cohort effects were estimated
(Germany was excluded from this part of the analysis
because of the restricted age range in this sample). The
ORs for the youngest cohorts compared with the oldest
cohorts range from 2.2 in Brazil to 10.9 in Japan, with
the ORs for seven of the nine countries being greater
than 5.
There is a striking discrepancy between the insignif-
icant associations between age and recent MDE in
Table 5 and the strongly consistent associations
between age and lifetime risk of MDE in Table 6.
Statistically, this discrepancy means that whereas
younger cohorts have higher reported rates of MDE, it
is less persistent (as indicated by the ratio of 12-month
to lifetime prevalence) in the younger than the older
cohorts. This lower persistence is not due to an inverse
relationship between time since onset and persistence,
as no such pattern was found in the data. A more likely
interpretation is that the increase in the proportion of
people who have a lifetime depressive episode in
recent cohorts is accompanied by a decrease in the
persistence of these new cases of depression.
Co-morbidity
Previous epidemiological studies have shown that
MDE is highly co-morbid with other mental disorders,
especially with anxiety disorders (Merikangas et al.,
1996; Kessler, 1997). The same is true for the ICPE
surveys. There were statistically significant co-
morbidities between MDE and all the anxiety
disorders assessed in the ICPE surveys (results not
shown, but available on the ICPE Web page
www.hcp.med.harvard.edu/icpe). Consistent with
previous research (Kessler et al., 1998b, 1999a), these
associations were strongest with generalized anxiety
disorder (ORs in the range 3.0 to 20.7) and
panic disorder (ORs in the range 4.3 to 23.9). In most
surveys, between one-third and half of respondents
with a lifetime history of MDE also had a history of at
least one anxiety disorder.
Previous research suggests that the age of onset of
anxiety disorders is typically earlier than the age
of onset of MDE among people with co-morbid
anxiety and depression (Kessler, 1995; Merikangas et
al., 1996). This is also the case in the ICPE surveys
































































































































































































































































































































































































































































































































































   
   
















































































   
   


























































































































































































































































































































































































































































































































































































































































































































IJMPR 12.1_crc  1/5/03  10:39 am  Page 12












































































































































































































































































































































































































































































































IJMPR 12.1_crc  1/5/03  10:39 am  Page 13
Andrade et al.14
(results not shown, but available on the ICPE Web
page www.hcp.med.harvard.edu/icpe). The proportion
of respondents with lifetime co-morbid anxiety-
depression, whose anxiety began at an earlier age than
their MDE, ranged from 53% in Germany to 80% in
the Czech Republic, while the proportion of those
whose MDE began at an earlier age than their anxiety
ranged from 16% in the US to 32% in Mexico. The
remainder had same-year onsets. It is noteworthy that
the same-year onsets, although smaller in number than
time-lagged onsets, were much more common
than one would expect on the basis of chance alone. 
Temporally primary anxiety disorders as predictors of
subsequent MDE
A previously published analysis of the ICPE survey
carried out in the US showed that temporally primary
anxiety disorders are powerful predictors of the subse-
quent first onset of MDE (Kessler et al., 1996). A
detailed analysis of the association between temporally
primary panic and subsequent MDE in the US survey
also showed that subsequent MDE was predicted
as strongly by panic attacks as panic disorder, and as
strongly by remitted panic as by active panic (Kessler
et al., 1998c). These results suggest that panic is more
likely to be a risk marker than a causal risk factor for
subsequent MDE. In other cases, though, only active
anxiety appears to predict MDE. This is true, for
example, for primary social anxiety disorder in the US
survey data (Kessler et al., 1999b).
The results in the ICPE surveys for the associations
of primary anxiety with later MDE are presented in
Table 7. These results are based on a series of discrete-
time survival equations (Efron, 1988) in which active
and remitted anxiety disorders were treated as time-
varying predictors of the first onset of MDE, controlling
for person-year, cohort, and gender. Several consistent
patterns can be seen in the data. Firstly, all active
primary anxiety disorders consistently and powerfully
predict the subsequent first onset of MDE, with
weighted mean ORs ranging from 9.4 for post-
traumatic stress disorder to 81.6 for generalized anxiety
disorder. Secondly, the associations between primary
anxiety and secondary MDE consistently decrease
significantly as the duration of the anxiety increases.
Thirdly, although remitted primary anxiety disorders
are substantially less powerful predictors than active
primary anxiety disorders, the weighted mean ORs
associated with most remitted anxiety disorders are
nonetheless greater than 2. The exceptions are
remitted post-traumatic stress disorder and agora-
phobia, neither of which significantly predicts MDE.
More elaborate analyses of these data (results not
shown) reveal that the decrease in the effects of active
disorders is consistently non-linear across all countries
and disorders. This is due to the extremely strong
same-year association noted above. If we divide each
measure of active anxiety disorders into two analyses –
(i) first onset in the same year as the onset of MDE and
(ii) onset at least one year prior to the onset of MDE –
the OR for the first of these two coefficients is consis-
tently much larger than that for the second. The
second OR in each pair is consistently significant in
these specifications and the evidence of temporal
decay in the magnitude of effects decreases substan-
tially. These last two results mean that statistically
significant effects of active primary anxiety in
predicting first onset of subsequent MDE persist for
many years after the onset of the anxiety. 
Speed of initial treatment contact
The ICPE surveys did not include a consistent set of
questions on treatment of MDE. As a result, it is
impossible to compare the rates of treatment across
countries. However, the surveys in Canada and the US
were carried out collaboratively and included identical
questions on service use. It is consequently possible to
say a few words about treatment that apply to these
two countries. We focus on only one aspect of
treatment: speed of initial treatment contact after the
first onset of MDE. This is an aspect of treatment that
is seldom examined, but one that can be studied. In
the Canadian and US surveys, respondents were asked
both about the age of onset of their MDE and about
the age at which they first consulted a professional
about their MDE. 
Previous analyses of these data compared the age-
of-onset reports to the age-of-contact reports and
revealed that delays in initial treatment seeking of
more than a decade were normal for both Canada and
the US (Olfson et al., 1998). These previous analyses
also showed that treatment contact has increased in
recent cohorts in both Canada and the US, and that
the speed of initial treatment contact is inversely
related to age-of-onset of MDE in both countries
(Olfson et al., 1998; Kessler et al., 1998d). The first of
these results is important because it means that
treatment rates are increasing over time. The second
IJMPR 12.1_crc  1/5/03  10:39 am  Page 14
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result is also important because it suggests that early
onset cases, which are often more persistent and severe
than later-onset cases (Rothschild and Zimmerman,
2002), have the longest delays in obtaining treatment.
Some limited information about the generalizability of
this pattern was obtained by including questions about
age of onset and speed of initial treatment contact in a
cross-national survey of members of patient advocate
groups in 11 countries around the world. This survey
was carried out by the Global Alliance of Mental
Illness Advocacy Networks (GAMIAN), an interna-
tional consortium of patient advocacy groups.
Consistent with the results reported in the ICPE
surveys, a strong inverse relationship between age of
onset and speed of initial treatment contact was found
across all countries in the GAMIAN survey
(Christiana et al., 2000).
Discussion
Caution is needed in interpreting the prevalence
estimates reported here because of limited evidence on
the reliability and validity of the different versions of
the CIDI in the countries where the surveys were
carried out. The lifetime prevalence estimates
obtained in the surveys carried out in the US
(UM–CIDI) and Germany (M–CIDI) are similar to
those obtained by clinicians in confirmatory re-inter-
views administered in conjunction with these two
surveys (American Psychiatric Association, 1994;
Kessler et al., 1998a). However, similar clinical confir-
mation interviews were not carried out in the other
countries. It is conceivable that the prevalence
estimates based on the original WHO–CIDI are less
accurate than those generated by the enhanced
versions of the instrument (UM-CIDI and M-CIDI) or
Table 7. The effects of temporally primary anxiety disorders in predicting first onset of major depressive episodes, all countries
combined
Active Remitted
Average effect Time trend for Average effect Time trend for 
onset in years years since onset
ORa 95% CIa ORa 95% CIa ORa 95% CIa ORa 95% CIa
I. Weighted mean associations across all 10 countries
Agoraphobia 16.8* 13.5–21.0 0.8* 0.8–0.9 1.7 0.8–3.5 1.0 0.8–1.1
Generalized anxiety 
disorder 81.6* 62.2–107.1 0.7* 0.6–0.7 4.7* 1.1–20.6 0.7 0.4–1.2
Obsessive-compulsive 
disorder 52.7* 25.5–109.0 0.7* 0.6–0.8 3.2 0.4–23.8 0.7* 0.7–0.8
Panic disorder 43.5* 29.8–63.4 0.8* 0.7–0.8 2.8 0.9–9.3 0.8 0.7–1.1
Post-traumatic stress 
disorder 9.4* 6.2–14.2 0.9* 0.8–0.9 0.9 0.4–2.27 1.1 1.0–1.3
Simple phobia 10.7* 8.6–13.3 0.9* 0.9–0.9 3.6* 2.2–5.7 1.0 0.9–1.0
Social anxiety disorder 11.9* 9.6–14.8 0.9* 0.8–0.9 2.1* 1.2–3.8 1.0 0.9–1.1
II. Range of within country associations
Agoraphobia 3.3–47.3* 0.7*–1.1 0.2*–56.3* 0.0*–1.3
Generalized anxiety 
disorder 20.7*–876.8* 0.1*–0.9 0.0*–33.5* 0.0*–1.1
Obsessive-compulsive 
disorder 3.0–877.3* 0.4*–0.9 —– 0.0*–0.4*
Panic disorder 6.8*–110.9* 0.6*–1.0 2.1–20.6* 0.5*–1.0
Post-traumatic stress disorder 3.6–23.6* 0.9*–1.0 0.2–1.1 1.1–1.4*
Simple phobia 0.6–43.2* 0.8*–1.2 0.2–47.6* 0.7–1.6*
Social anxiety disorder 5.9*–28.2* 0.8*–0.9* 1.0–8.9* 0.1*–1.3
a OR = odds ratio, 95% CI = 95% confidence interval
* Significant at the 0.05 level, two-sided test
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that the CIDI diagnoses are less consistent with
clinical diagnoses for other time frames (12-month
and 30-day prevalence) than for lifetime prevalence. 
The substantial cross-national variation in the
estimated prevalence of MDE in the ICPE surveys is
broadly consistent with the results of the previous
cross-national epidemiological surveys that were
reviewed in the introduction. It is interesting to note
that these previous surveys consistently find the lowest
prevalence estimates in Asian countries (Weissman et
al., 1996), as do cross-national surveys of depression in
primary care samples (Simon et al., 2002). The finding
that Japan has by far the lowest prevalence in the
ICPE surveys is consistent with this fact. It is not clear
why prevalence is lower in Asian countries, nor why
the larger pattern of cross-national differences exists.
The broad substantive possibilities include cross-
national differences in genetic vulnerability and
environmental risk factors, and methodological possi-
bilities include cross-national differences in the
relevance of DSM criteria, in the sensitivity and speci-
ficity of the CIDI symptom questions, and in the
willingness of respondents to admit depressive
symptoms in an interview. 
Simon et al. (2002), in a report from the WHO
Psychological Problems in General Health Care
(PPGHC) study (Christiana et al., 2000), shed some
light on the methodological possibilities by showing
that the clustering of depressive symptoms is
consistent across PPGHC sites in 15 countries
worldwide. This finding argues indirectly that DSM
criteria are equally relevant and CIDI questions
equally sensitive and specific across these countries.
Simon and colleagues also found a strong dose-
response relationship between the number of
depressive symptoms and role impairment in all parts
of the world. However, the level of role impairment
among people with a given number of depressive
symptoms was found to be inversely related to the
estimated prevalence of depression, raising the possi-
bility that cross-national prevalence differences might
be due, at least in part, to cultural differences in the
threshold for reporting depressive symptoms. This
possibility cannot be investigated in the ICPE surveys
due to between-survey differences in the specific items
used to assess disorders. 
Within the context of this limitation in the
accuracy of between-country prevalence differences,
the ICPE prevalence estimates are consistent with
those of other community epidemiological surveys in
suggesting that MDE is a commonly occurring disorder
in many countries throughout the world (Weissman et
al., 1996). Furthermore, the results of our indirect
evaluation of persistence are consistent with long-term
prospective studies (Hagnell and Grasbeck, 1990;
Murphy et al., 1986; Steinhausen et al., 1998) in
suggesting that MDE is a chronic episodic disorder
that often persists throughout the life course. Our
results regarding early age of onset are consistent with
the finding of high prevalence of MDE in epidemio-
logical studies of adolescents (Murphy et al., 1986).
The substantial persistence of MDE is especially
important in light of the evidence that persistent
depression can have a devastating effect on role
functioning and quality of life (Rice et al., 1990;
Wohlfarth et al., 1993; Kessler and Frank, 1997). For
example, Wells and colleagues showed that the effects
of MDE are comparable with, and in some cases
greater than, the effects of such chronic physical
disorders as hypertension, diabetes, and arthritis, to
name only a few (Wells et al., 1989). Moreover,
because of its early age of onset compared with most
chronic disorders, MDE has powerful adverse effects
on critical life-course transitions such as educational
attainment (Kessler et al., 1995), teenage childbearing
(Kessler et al., 1997a) and marital instability (Kessler
et al., 1998e). It is surprising, in light of the evidence
about these effects of MDE on subsequent life
adversity, that evidence for a socioeconomic gradient
in MDE is less clear in the ICPE surveys than in
previous epidemiological studies (Canino et al., 1987;
Bland et al., 1988a; Hwu et al., 1989; Lépine et al.,
1989; Wells et al., 1989; Lee et al., 1990; Wittchen et
al., 1992). Twelve-month MDE is inversely related to
family income in the ICPE surveys carried out in the
US and the Netherlands, but there is no meaningful
income gradient in 12-month MDE in the other
countries that assessed family income. Nor is there a
meaningful association between education and 12-
month MDE in any of the ICPE countries other than
the US. This intriguing difference between countries
in the effects of socioeconomic status requires more in-
depth investigation. The ICPE surveys are consistent
with previous surveys in confirming the finding that
MDE is more common among women than men and
among the unmarried than the married.
The consistent finding of increasing lifetime preva-
lence of MDE across successively more recent cohorts
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is broadly consistent with the results of other recent
epidemiological surveys (Robins and Regier, 1991;
Cross-National Collaborative Group, 1992).
Methodological factors, such as age-related differential
recall or differential willingness to disclose the
disorder, could play an important part in accounting
for this pattern (Giuffra and Risch, 1994; Simon and
Von Korff, 1995). However, other data patterns
discussed elsewhere (Kessler et al., 1994; Kessler,
2000) are also consistent with there being a genuine
increase in the prevalence of MDE in recent cohorts.
One of the most telling of these patterns is the finding
that the effects of early life adversities in predicting
MDE are consistent across cohorts (Kessler et al.,
1997b), a finding one would not expect if the apparent
cohort effect was due entirely to recall failure. At the
same time, it is likely that at least part of the apparent
cohort effect is due to recall failure. It is noteworthy in
this regard that the ICPE surveys show consistent
evidence of lower persistence of MDE in recent
cohorts, a finding that could be due to respondents in
older cohorts selectively remembering more persistent
and severe disorders. If this is so, then the actual
lifetime prevalence of MDE might be considerably
higher than estimated in the ICPE surveys and the
actual chronicity of MDE might be lower than
estimated in the ICPE surveys.
The finding that MDE is highly co-morbid with
anxiety disorders is consistent with studies in both
community samples (Merikangas et al., 1996) and
clinical samples (Stein et al., 1995), as is the finding that
anxiety disorders typically have an earlier age of onset
than MDE (Bebbington, 1998). The kind of analysis
reported here on primary anxiety disorders predicting
subsequent MDE, however, has not been carried out in
previous epidemiological surveys with the exception of
the US survey (Kessler, 1997; Kessler et al., 1996; Kessler
et al., 1998f). The results show that temporally primary
anxiety disorders are powerful predictors of the subse-
quent first onset of MDE. It is less clear, though, whether
this is true because anxiety disorders are causal risk
factors for MDE or only markers of other more funda-
mental causes. If anxiety disorders are causal risk factors,
we would expect that treatment and resolution of the
anxiety disorders would help reduce the risk of the subse-
quent onset of MDE, while this would not be true if
anxiety disorders were risk markers. 
It is tempting to draw the conclusion that anxiety
disorders are causal risk factors, based on the finding that
active anxiety disorders are more powerful predictors of
MDE than are remitted anxiety disorders. However,
several other plausible causal mechanisms could bring
about this specification. It might be, for example, that
persistent anxiety disorders are associated with greater
environmental adversity and/or genetic predisposition to
MDE than remitted anxiety disorders, in which case the
persistence of anxiety would be a marker of underlying
causal factors that would not be affected by the
treatment and resolution of the anxiety. However, there
are at least two broad possibilities that are consistent
with the assertion that persistent anxiety creates genuine
risk for MDE. The first possibility is that MDE might, in
some cases, be a resignation response that occurs once
other attempts to resolve anxiety have been exhausted
(Aksikal, 1984). The second possibility is that primary
anxiety disorders might have neurological effects that
predispose to MDE (Wittchen et al., 2000). If either of
these possibilities is true, we would expect that
resolution of the anxiety prior to the onset of the MDE
would be successful in preventing the proportion of
MDE cases that occur as a result of these processes. 
The obvious broad-gauged test of these possibilities
– an experimental treatment effectiveness trial that
treats primary anxiety disorders and follows up both
cases and controls for a sufficiently long period of time
to determine whether the intervention has signifi-
cantly reduced the risk of secondary MDE – has never
been carried out. Given the age-of-onset distributions
of anxiety and depression, such a study would ideally
focus on screening, outreach, and treatment of adoles-
cents with primary anxiety disorders and would follow
these adolescents through the transition into early
adulthood in order to track intervention effects. Even if
the intervention did not prevent the onset of secondary
MDE, there is the question of whether it might
influence the course of MDE. We know that anxious-
depression is generally more persistent and severe than
pure depression (O’Leary et al., 2000). This being the
case, a reasonable question is whether the course of
depressive episodes would be less persistent and severe
if previously existing anxiety disorders were effectively
treated prior to the onset of the MDE. 
We have little non-experimental evidence to go
on in making even a provisional evaluation of the
likely effects of the treatment of primary anxiety on
subsequent depression. An exception is the work of
Goodwin and Olfson (2001), which showed that the
risk of subsequent MDE among survey respondents
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with prior panic disorder was lower for those who
received treatment for their panic than for those
who did not. Based on this result, Goodwin and
Olfson argued that treatment of primary panic might
reduce the risk of developing MDE. It is noteworthy
that this finding runs counter to the obvious non-
causal interpretation of the association between
primary anxiety and later MDE, which is  that
persistent-severe anxiety is a risk marker rather than
a causal risk factor. If this non-causal interpretation
were true, we would expect to find that survey
respondents who received treatment for their panic
would have a higher risk of subsequent MDE than
those whose panic was untreated due to the selection
bias for the most severe cases to have the highest
probability of seeking treatment. Indeed, Goodwin
and Olfson found the opposite pattern suggests that
the causal interpretation has some plausibility.
Finally, the evidence reviewed from the ICPE
Canadian and US surveys regarding speed of initial
treatment contact is encouraging in that it shows an
increase in treatment over successively more recent
cohorts. This result is consistent with recent reports of
increases in treatment of MDE based on trend studies
of treatment records (Zito et al., 2002; Olfson et al.,
2002). However, the finding that, despite this secular
trend, treatment delays are longer for retrospectively
reported early onset cases than later onset cases is
discouraging. This is especially true in light of
evidence concerning adverse effects of early-onset
disorders on critical life-course transitions, such as
schooling (Kessler et al., 1995), teen childbearing
(Kessler et al., 1997a), marital timing (Forthofer,
1996), and marital stability (Kessler et al., 1998e).
Importantly, the vast majority of early-onset depres-
sives experience these adverse life effects before they
obtain any professional treatment (Christiana et al.,
2000). There is no systematic research on the effec-
tiveness of early outreach and treatment of early onset
MDE in preventing these adverse effects, or on the
impact of the prevention of such effects on the subse-
quent course of early onset MDE. As noted above, we
do know that early onset MDE is more persistent and
severe than later onset MDE. It is conceivable that at
least part of the reason for this is that early onset MDE
has structural effects (for example, effects on educa-
tional attainment, teen childbearing, marital
disruption) that create lifelong structural vulnerabil-
ities to recurrence. If so, then early treatment of MDE
might be effective in influencing the subsequent
illness course by reducing the risk of the onset of struc-
tural vulnerabilities. Another potentially important
benefit of early outreach and treatment is that it might
reduce the probability of neurological effects that are
associated with depressive episodes becoming
endogenous as the number of episodes increases (Weiss
et al., 1998).
A great practical appeal of outreach and treatment of
early onset MDE from a public health perspective is that
most such cases occur during the school years. This
means that screening and outreach can be carried out
inexpensively by using schools for group screening. It
might also be possible to co-ordinate treatment with the
school system either by using school nurses to partic-
ipate in outreach and treatment or by using the physical
space of school classrooms during evenings and
weekends as a site for delivering services. The avail-
ability of effective treatments for adolescent depression,
reviewed by Ryan in this volume, adds to the appeal of
this approach. In light of these considerations, the
development and evaluation of the long-term effects of
such school-based early screening, outreach, and
treatment programs are important areas for future work.
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